Pfizer links up with heart disease AI developer Anumana to build cardiac amyloidosis diagnostics

Related Articles
Migraine with aura identified as independent risk factor for A-fib
Medical Xpress: Patients with migraine with aura (MwA) have significantly higher artificial intelligence-enabled electrocardiogram (AI-ECG) atrial fibrillation (AF) prediction model output, according to a study from Mayo Clinic published online…August 03, 2022
Supporting Predictive Analytics to Improve Clinical Decision Making and Patient Outcomes
As we strive to improve clinical decison making and patient outcomes – predictive analytics are a wonderful tool to help us in that goal. But you can’t just decide to throw predictive analytics into…November 26, 2025
How a New AI Algorithm Could Help in the Early Detection of Heart Disease
Xtalks: An AI algorithm developed by researchers at the Mayo Clinic through its newly formed health technology company Anumana Inc., can assess for low ejection fraction through routine electrocardiograms (ECG,…May 16, 2021
Pfizer and Anumana boost detection of cardiovascular disease
Pharma Times: Artificial intelligence (AI) health technology company, Anumana, will collaborate with Pfizer to develop an artificial intelligence electrocardiogram algorithm (AI-ECG), which enables the early detection of cardiac amyloidosis.December 16, 2022


